Investment Summary

Morgan Stanley Private Equity Asia Invests In KNX

On January 1, 2017, private equity firm Morgan Stanley Private Equity Asia invested in software company KNX

Investment Highlights
  • This is Morgan Stanley Private Equity Asia’s 1st transaction in the Software sector.
  • This is Morgan Stanley Private Equity Asia’s 16th transaction in China.

Investment Summary

Date 2017-01-01
Target KNX
Sector Software
Investor(s) Morgan Stanley Private Equity Asia
Deal Type Growth Capital

Target

KNX

Shanghai, China
KNX is a human resources consulting and management training company. KNX was founded in 2008 and is based in Shanghai, China.

Search 207,199 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Investor(S) 1

DESCRIPTION

Morgan Stanley Private Equity Asia is a direct investment affiliate of Morgan Stanley that looks to acquire minority investments in companies with substantial business operations throughout Asia. The Unit has a preference for fast-growing businesses with strong brands and sustainable competitive advantages. In addition to minority deals, the Firm will also consider select control situations. Morgan Stanley Private Equity Asia was formed in 1993 and is headquartered in Hong Kong.


DEAL STATS #
Overall 22 of 36
Sector: Software M&A 1 of 1
Type: Growth Capital M&A Deals 12 of 19
Country: China M&A 16 of 19
Year: 2017 M&A 1 of 3
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-11-18 Buchang Pharmaceutical

Heze, China

Buchang Pharmaceutical is principally engaged in R&D, production and sales of traditional Chinese medicines (”TCM”) in China with a focus on the cardiovascular diseases therapeutic area. Buchang produces branded, patented, and mostly prescription-only TCM in different delivery formats. Buchang’s products can found in 15,000 hospitals and 150,000 drug stores across China and have been used by more than 50 million patients. Buchang Pharmaceutical was founded in 1993 and is based in Heze, China.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-01-30 ZCL Chemicals

Mumbai, India

ZCL Chemicals is one of the fastest-growing manufacturers of specialty active pharmaceutical ingredients (APIs) and advanced intermediates. ZCL’s highly specialized approach focuses on niche therapeutic areas, underpinned by complex chemistry, supported by a state-of-the-art U.S. Food and Drug Administration (FDA) approved facility, along with strong research & development capabilities. ZCL Chemicals is based in Mumbai, Maharashtra.

Buy -